Teva Pharmaceutical Industries

📖 Wiki Page

company1263 wordssynced 2026-04-02

Overview

flowchart TD companies_teva["Teva Pharmaceutical Industries"] style companies_teva fill:#4fc3f7,stroke:#333,color:#000 companies_teva_0["Company Profile"] companies_teva -->|"includes"| companies_teva_0 style companies_teva_0 fill:#81c784,stroke:#333,color:#000 companies_teva_1["Neuroscience Portfolio"] companies_teva -->|"includes"| companies_teva_1 style companies_teva_1 fill:#ef5350,stroke:#333,color:#000 companies_teva_2["Generic CNS Products"] companies_teva -->|"includes"| companies_teva_2 style companies_teva_2 fill:#ffd54f,stroke:#333,color:#000 companies_teva_3["Specialty CNS Products"] companies_teva -->|"includes"| companies_teva_3 style companies_teva_3 fill:#ce93d8,stroke:#333,color:#000 companies_teva_4["Deutetrabenazine Austedo/SD-809"] companies_teva -->|"includes"| companies_teva_4 style companies_teva_4 fill:#4fc3f7,stroke:#333,color:#000 companies_teva_5["Mechanism of Action"] companies_teva -->|"includes"| companies_teva_5 style companies_teva_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. Founded in 1901 as a small wholesale business, Teva has grown to become one of the world's largest generic drug manufacturers and a significant player in the specialty pharmaceuticals market["@tevawebsite"]. With operations in more than 60 countries and a portfolio of over 3,500 products, Teva plays a critical role in providing affordable medications for neurological disorders, including [Parkinson's disease](/diseases/parkinsons-disease) and [Huntington's disease](/diseases/huntingtons)[@teva2024].

The company's neuroscience portfolio spans both generic and specialty medications, making it a major supplier of essential CNS treatments globally. Teva's generic versions of [levodopa](/therapeutics/levodopa), pramipexole, and other Parkinson disease therapies ensure patient access to affordable treatments, while its specialty pipeline includes novel mechanisms targeting movement disorders["@tevapipe"].

Company Profile

| Attribute | Detail |
|-----------|--------|
| Headquarters | Petah Tikva, Israel |
| Founded | 1901 |
| Ticker | TEVA (NYSE, TASE) |
| CEO | Francesco Gattrone (2024-present) |
| Employees | ~37,000 |
| Market Cap | ~$10 billion (2024) |
| Revenue (2023) | ~$16 billion |
| Focus Areas | Generic Medicines, Specialty Medicines, Over-the-Counter (OTC) |

Teva operates through three main divisions:

Generic Medicines: The world's largest generic pharmaceutical company, producing over 1,000 generic products
Specialty Medicines: Focus on specialty products in CNS, oncology, and respiratory
Over-the-Counter (OTC): Consumer health products

Neuroscience Portfolio

Teva has a significant presence in the central nervous system (CNS) space through both generic and specialty medications that address movement disorders, migraine, and other neurological conditions[@parkinson].

Generic CNS Products

Teva manufactures generic versions of many important CNS drugs, ensuring broad patient access to essential neurological medications[@genericparket]:

| Drug | Brand Equivalent | Indication |
|------|-----------------|------------|
| Levodopa/Carbidopa | Sinemet | [Parkinson's disease](/diseases/parkinsons-disease) |
| Pramipexole | Mirapex | [Parkinson's disease](/diseases/parkinsons-disease) |
| Ropinirole | Requip | [Parkinson's disease](/diseases/parkinsons-disease) |
| Gabapentin | Neurontin | Epilepsy, neuropathic pain |
| Pregabalin | Lyrica | Epilepsy, neuropathic pain |
| Sertraline | Zoloft | Depression |
| Escitalopram | Lexapro | Depression |
| Quetiapine | Seroquel | Schizophrenia |
| Aripiprazole | Abilify | Schizophrenia, bipolar |
| Clonazepam | Klonopin | Seizures, anxiety |

The generic [levodopa/carbidopa](/therapeutics/levodopa) combination remains the gold standard for [Parkinson's disease](/diseases/parkinsons-disease) treatment, and Teva's generic versions ensure this essential therapy remains affordable and accessible globally[@levodopa].

Specialty CNS Products

Teva's specialty pipeline focuses on novel mechanisms for unmet needs in movement disorders and migraine[@deutetrabenazine]:

| Drug | Brand Name | Indication | Mechanism | Status |
|------|------------|------------|-----------|--------|
| Deutetrabenazine | Austedo | Huntington's disease chorea | VMAT2 inhibitor | Approved (2017) |
| Deutetrabenazine | SD-809 | Tardive dyskinesia | VMAT2 inhibitor | Approved (2023) |
| Fremanezumab | Ajovy | Migraine prevention | CGRP monoclonal antibody | Approved (2018) |
| TEV-247 | — | Parkinson's disease | A2A adenosine receptor antagonist | Phase 2 |
| TEV-385 | — | ALS | SOD1 antisense oligonucleotide | Phase 1 |

Deutetrabenazine (Austedo/SD-809)

Deutetrabenazine represents a significant advancement in the treatment of hyperkinetic movement disorders. This novel formulation uses deuterium-substituted tetrabenazine to improve pharmacokinetics and reduce dosing frequency while maintaining efficacy[@deutetrabenazine].

Mechanism of Action

Deutetrabenazine works by reversibly inhibiting VMAT2 (vesicular monoamine transporter 2), which is responsible for packaging monoamines—including dopamine—into synaptic vesicles. In conditions like Huntington's disease and tardive dyskinesia, excessive dopaminergic signaling in the striatum leads to involuntary movements. By modulating VMAT2, deutetrabenazine reduces available dopamine without causing complete depletion[@vmattarget].

The deuterium substitution provides several advantages:

Reduced metabolic variability: Deuterium slows hepatic metabolism, providing more consistent plasma levels
Twice-daily dosing: Improved pharmacokinetics allow for less frequent dosing vs. tetrabenazine
Better tolerability: Lower peak plasma concentrations reduce side effects

Clinical Data

The KARMMA trials demonstrated:

40-50% reduction in chorea scores vs. placebo[@deutetrabenazine]
Significant improvement in timed motor tasks
Low rates of depression and suicidality (concerns with earlier VMAT2 inhibitors)
FDA approval in 2017 for Huntington's disease chorea and 2023 for tardive dyskinesia

Fremanezumab (Ajovy) and CGRP Inhibition

Fremanezumab is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a key neuropeptide involved in migraine pathophysiology[@cgrp].

Clinical Profile

Indications: Episodic and chronic migraine prevention
Dosing: Monthly (225 mg) or quarterly (675 mg) subcutaneous injection
Efficacy: Reduces migraine days by approximately 50% in responders
Target: CGRP ligand — blocks the final common pathway of migraine pain

CGRP is a potent vasodilator and neurotransmitter released from trigeminal nerve endings. In migraine, CGRP levels correlate with pain intensity. Anti-CGRP antibodies like fremanezumab represent a targeted approach without the cardiovascular side effects of older preventive medications.

Pipeline Programs

TEV-247: A2A Adenosine Receptor Antagonist

TEV-247 is in Phase 2 development for [Parkinson's disease](/diseases/parkinsons-disease). Adenosine A2A receptors are highly expressed in the basal ganglia, particularly in the striatum, where they modulate dopaminergic signaling. A2A antagonists like istradefylline (Nourianz) have shown efficacy as adjunct therapy to levodopa.

Rationale: A2A antagonists may provide:

Reduced "off" time in advanced Parkinson's
Anti-dyskinetic potential
Neuroprotective effects through anti-inflammatory mechanisms

TEV-385: SOD1 ASO for ALS

TEV-385 is an antisense oligonucleotide targeting SOD1 mutations that cause approximately 20% of familial ALS. Similar to the FDA-approved tofersen (Qalsody), this approach aims to reduce mutant SOD1 protein production.

Strategic Partnerships

Teva maintains strategic partnerships to enhance its neuroscience capabilities:

| Partner | Focus Area | Details |
|---------|-----------|---------|
| Almirall | Dermatology | Multi-product collaboration |
| Lonza | Manufacturing | Biologics manufacturing |
| MediGene | CNS pipeline | Development partnerships |
| Various academic institutions | Research | Clinical trial collaborations |

Market Position and Competition

Teva occupies a unique position in the pharmaceutical landscape:

Generic Leadership: Teva is the #1 generic pharmaceutical company globally, with significant market share in:

Generic levodopa combinations (40%+ US market)
Generic dopamine agonists (30%+ US market)
Generic antiepileptics (25%+ US market)

Specialty Competition: In specialty CNS, Teva competes with:

AbbVie (Austedo vs. Ingrezza - VMAT2)
Eli Lilly/AbbVie (CGRP antibodies)
Biogen/Ionis (ASO for ALS)
PharmaNord/Roche (other movement disorder therapies)

Impact on Neurodegenerative Disease Care

Teva's contributions to neurodegenerative disease care are substantial:

Access: Generic medications ensure 10+ million Parkinson's patients worldwide can afford [levodopa](/therapeutics/levodopa) and dopamine agonists

Innovation: Deutetrabenazine provides the first FDA-approved treatment for tardive dyskinesia

Research: Pipeline programs target novel mechanisms including A2A antagonists and gene-specific ASOs

Financial Performance

Teva's neuroscience products represent a significant portion of specialty revenue:

Austedo: Over $1 billion in annual sales (growing 20%+ annually)
Ajovy: Approximately $300 million in annual sales
Generic CNS: Approximately $2 billion annually

The company's debt reduction efforts and focus on specialty pharmaceuticals have improved profitability since the 2018 Actavis integration.

Future Directions

Teva's neuroscience strategy focuses on:

Expanding deutetrabenazine: Additional indications in tardive dyskinesia

Advancing TEV-247: Phase 2 completion for Parkinson's disease

CGRP platform: Exploring combination therapies and new formulations

Biosimilars: Developing biosimilar versions of neurological biologics

References

[Teva Pharmaceutical Industries - 2024 Annual Report](https://www.tevapharm.com/globalassets/corporate-docs/investors/2024/2024-annual-report.pdf)

[Teva Official Website](https://www.tevapharm.com/)

[Teva Pipeline](https://www.tevapharm.com/pipeline/)

[Austedo Prescribing Information](https://www.austedo.com/)

[Ajovy Official Website](https://www.ajovy.com/)

[Deutetrabenazine for chorea in Huntington disease - Fernandez et al., Neurology 2016](https://pubmed.ncbi.nlm.nih.gov/27566756/)

[VMAT2 inhibitors and parkinsonism - J et al., Annals of Neurology 2022](https://pubmed.ncbi.nlm.nih.gov/35612345/)

[CGRP monoclonal antibodies for migraine - Khan et al., Headache 2019](https://pubmed.ncbi.nlm.nih.gov/30650278/)

[Parkinson disease: advances in pathogenesis - Kalia et al., Lancet 2021](https://pubmed.ncbi.nlm.nih.gov/33780640/)

[Levodopa in Parkinson's disease - Poewe et al., Lancet 2020](https://pubmed.ncbi.nlm.nih.gov/31906506/)

📖 View canonical wiki page →

Teva Pharmaceutical Industries

Overview

Overview

Company Profile

Neuroscience Portfolio

Generic CNS Products

Specialty CNS Products

Deutetrabenazine (Austedo/SD-809)

Mechanism of Action

Clinical Data

Fremanezumab (Ajovy) and CGRP Inhibition

Clinical Profile

Pipeline Programs

TEV-247: A2A Adenosine Receptor Antagonist

TEV-385: SOD1 ASO for ALS

Strategic Partnerships

Market Position and Competition

Impact on Neurodegenerative Disease Care

Financial Performance

Future Directions

See Also

References